QNTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Quantum Biopharma Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 26, 2026
$2.41−0.06 (-2.43%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Quantum Biopharma has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Quantum Biopharma filed with the SEC
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s
EX-99.1 to Form 6-K
BioPharma Ltd. Announces Corporate Updates
EX-99.2 to Form 6-K
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION
EX-99.3 to Form 6-K
Ltd. (formerly, FSD Pharma Inc.)
EX-99.1 to Form 6-K
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA
EX-99.2 to Form 6-K
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS
EX-99.1 to Form 6-K
For the three months ended
EX-99.1 to Form 6-K
BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.)
EX-99.2 to Form 6-K
of Interim Filings Full Certificate
EX-99.3 to Form 6-K
Quantum BioPharma Submits Investigational New Drug (IND) Application
EX-99.1 to Form 6-K
BioPharma Ltd. Provides Corporate Update
EX-99.1 to Form 6-K
Ltd. (formerly, FSD Pharma Inc.)
EX-99.1 to Form 6-K
QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA
EX-99.2 to Form 6-K
I, Zeeshan Saeed, the Chief Executive Officer of Quantum BioPharma
EX-99.3 to Form 6-K